Skip to content

Study · In vitro (cells) · 2015

5 results

The oncolytic peptide LTX-315 triggers necrotic cell death.

Forveille S, Zhou H, Sauvat A, Bezu L, Müller K, Liu P, Zitvogel L, Pierron G, Rekdal Ø, Kepp O, Kroemer G

Cell cycle (Georgetown, Tex.)1 Jan 2015Cited by 33 (Europe PMC)

PMID26566869 (opens in a new tab)PMCIDPMC4825625 (opens in a new tab)DOI10.1080/15384101.2015.1093710 (opens in a new tab)PepBankPUB-26566869
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In tumor cells, LTX‑315 failed to induce apoptotic nuclear condensation.

    In plain wordsIn cells, LTX‑315 did not induce the nuclear changes associated with apoptosis.

    Peptide
    LTX-315
    Outcome
    No significant changeApoptotic nuclear condensation
    Study

    n: not reported in source

    Tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Transmission electron microscopy or morphometric analysis of chromatin-stained tumor cells revealed that LTX-315 failed to induce apoptotic nuclear condensation and rather induced a necrotic phenotype.
  2. 02LabIn vitro (cells)Mechanism

    In tumor cells, LTX‑315 induced a necrotic phenotype.

    In plain wordsIn cells, LTX‑315 induced a necrotic phenotype.

    Peptide
    LTX-315
    Outcome
    IncreaseNecrotic phenotype
    Study

    n: not reported in source

    Tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Transmission electron microscopy or morphometric analysis of chromatin-stained tumor cells revealed that LTX-315 failed to induce apoptotic nuclear condensation and rather induced a necrotic phenotype.
  3. 03LabIn vitro (cells)Mechanism

    In tumor cells, LTX‑315 failed to stimulate caspase-3 activation.

    In plain wordsIn cells, LTX‑315 did not stimulate caspase-3 activation.

    Peptide
    LTX-315
    Outcome
    No significant changeCaspase-3 activation
    Study

    n: not reported in source

    Tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, LTX-315 failed to stimulate the activation of caspase-3
  4. 04LabIn vitro (cells)Mechanism

    In tumor cells, caspase inhibition with Z-VAD-fmk did not reduce LTX‑315-induced cell killing.

    In plain wordsIn cells, Z-VAD-fmk did not reduce cell killing by LTX‑315.

    Peptide
    LTX-315
    Outcome
    No significant changeCell killing with caspase inhibition
    Study

    n: not reported in source

    Tumor cells
    Comparator
    LTX-315 without caspase inhibition
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, LTX-315 failed to stimulate the activation of caspase-3, and inhibition of caspases by means of Z-VAD-fmk was unable to reduce cell killing by LTX-315.
  5. 05LabIn vitro (cells)Mechanism

    In tumor cells, necrostatin-1 and cyclosporin A failed to reduce LTX‑315-induced cell death.

    In plain wordsIn cells, necrostatin-1 and cyclosporin A did not reduce LTX‑315-induced cell death.

    Peptide
    LTX-315
    Outcome
    No significant changeCell death with necroptosis inhibitors
    Study

    n: not reported in source

    Tumor cells
    Comparator
    LTX-315 without the inhibitors
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, 2 prominent inhibitors of regulated necrosis (necroptosis), namely, necrostatin-1 and cycosporin A, failed to reduce LTX-315-induced cell death.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.